Sigvotatug Vedotin

Summary

Sigvotatug Vedotin (CHEMBL5314879) is a phase-3 clinical-stage antibody drug conjugate; indicated across 2 conditions including non-small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314879
Name	Sigvotatug Vedotin
Type	Antibody drug conjugate
Max phase	3

Also known as: Sigvotatug vedotin, Sigvotatug vedotina, Sigvotatug vedotine, SIGVOTATUG VEDOTIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neoplasm	2	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06012435	PHASE3	ACTIVE_NOT_RECRUITING	A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06758401	PHASE3	RECRUITING	This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT07227298	PHASE1/PHASE2	RECRUITING	Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT04389632	PHASE1	RECRUITING	A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT06549816	PHASE1	COMPLETED	A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).